DURHAM, N.C., July 27, 2015 (GLOBE NEWSWIRE) -- Heat Biologics, Inc. ("Heat" or the "Company") (NASDAQ:HTBX), a clinical stage biopharmaceutical company focused on the development of cancer immunotherapies, today announced the promotions of Taylor Schreiber, M.D., Ph.D., to Chief Scientific Officer, and Melissa Price, Ph.D., to Vice President of Product Development. Dr. Schreiber, who previously served as Vice President of Research and Development, will continue to be responsible for leading the Company's research efforts including its ImPACT and ComPACT Therapy drug development platforms. Dr. Price, whose previous role was Vice President of Clinical and Regulatory Affairs, will continue to lead Heat's product development efforts, which include directing the Company's clinical development, regulatory and manufacturing strategy.
"Both Taylor and Melissa have been instrumental in progressing Heat's research and clinical programs and are deeply deserving of these promotions," said Mr. Wolf. "With interim data from the ongoing Phase 2 trial of HS-110 in non-small cell lung cancer and the completion of enrollment in the Phase 2 trial of HS-410 in bladder cancer expected in 2015, having accomplished individuals like Taylor and Melissa in key leadership positions is critical to our future success."
"As the co-inventor of significant elements of Heat's technology platforms, Taylor is an emerging leader in immunotherapy," continued Mr. Wolf. "Melissa has successfully led numerous oncology programs from initiation through completion. I look forward to continuing to work closely with Taylor and Melissa as we continue to execute our research and clinical development plan."
About Heat Biologics, Inc.
Heat Biologics, Inc. (www.heatbio.com) is a clinical-stage biopharmaceutical company focused on developing its novel, "off-the-shelf" ImPACT™ therapeutic vaccines to combat a wide range of cancers. Our ImPACT™ Therapy is designed to deliver live, genetically-modified, irradiated human cells which are reprogrammed to "pump out" a broad spectrum of cancer-associated antigens together with a potent immune adjuvant called "gp96" to educate and activate a cancer patient's immune system to recognize and kill cancerous cells. Heat is conducting a Phase 2 trial of its viagenpumatucel-L (HS-110) in patients with non-small cell lung cancer as well as a Phase 2 trial with its vesigenurtacel-L (HS-410) in patients with non-muscle invasive bladder cancer.
Forward Looking Statements
This press release includes forward-looking statements on our current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "should," "potential," "continue," "expects," "anticipates," "intends," "plans," "believes," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and include statements regarding the continued efforts of Drs. Schreiber and Price, the expected timing of interim data from the ongoing trial of HS-110, and completion of enrollment in the Phase 2 trial of HS-410 and the potential for impact of Heat's ImPACT™ Therapy. These statements are subject to a number of risks and uncertainties, many of which are difficult to predict, including the ability for Heat's ImPACT™ Therapy to perform as designed, the ability to timely enroll patients and complete the clinical trial on time, the other factors described in our annual report on Form 10-K for the year ended December 31, 2014 and Heat's other filings with the SEC. The information in this release is provided only as of the date of this release, and we undertake no obligation to update any forward-looking statements contained in this release based on new information, future events, or otherwise, except as required by law.
CONTACT: Heat Biologics, Inc. Jeff Wolf Chief Executive Officer 919-240-7133 [email protected] Investor Relations & Media Inquiries Michael Wood LifeSci Advisors, LLC 646-597-6983 [email protected]